Table 2 Univariate linear regression of factors associated with B12 levels at time of diagnosis
From: Vitamin B12 measurements across neurodegenerative disorders
| Diagnosis | Coefficient | (95% CI) | P-value |
|---|---|---|---|
| Parkinson’s disease | Ref | ||
| Alzheimer’s disease | 10.4 | (−27.7, 48.5) | 0.59 |
| Dementia with Lewy bodies | 63.9 | (−0.06, 128) | 0.05 |
| Frontotemporal dementia | 88.2 | (12.7, 164) | 0.02 |
| Mild cognitive impairment | 44.6 | (9.77, 80.5) | 0.015 |
| Multiple systems atrophy | 95.0 | (−22.1, 212) | 0.11 |
| Progressive supranuclear palsy | 84.4 | (2.74, 166) | 0.04 |
| Female gender | −9.56 | (−35.2, 16.1) | 0.47 |
| Age at diagnosis | −0.99 | (−2.28, 0.29) | 0.13 |
| Multivitamin use | 91.1 | (62.4, 120) | < 0001 |
| B12 supplementation | 88.7 | (35.3, 142) | 0.001 |
| Metformin | 23.0 | (−26.3, 72.3) | 0.36 |
| Proton Pump Inhibitor | 0.62 | (−34.2, 35.5) | 0.97 |